Hi, everyone. Let's get started. Welcome to the 44th Annual JPMorgan Healthcare Conference. My name is Priyanka Grover, and I'm part of the JPMorgan Biotech team. Today, our next presenting company is ...
• Recursion Pharmaceuticals’ stock rises 8% in pre-market to $5.08 after positive trial results. • The Phase 1B/2 TUPELO trial indicates significant reductions in polyp burden for REC-4881, enhancing ...
How many times a week do you introduce yourself? Whether it’s in person, virtually, one-on-one, in a large group, or formally or informally, you probably introduce yourself many times a week. Perhaps ...
Creating simple data classes in Java traditionally required substantial boilerplate code. Consider how we would represent Java’s mascots, Duke and Juggy: public class JavaMascot { private final String ...
This AI company isn't yet living up to the hype. Let's discuss Recursion Pharmaceuticals' performance over the past four years and whether the company can deliver solid returns in the future. It can ...
Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to beat earnings when it reports second-quarter 2025 results on Aug. 5 ...
The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. The company reported ...
Abstract: Current synthetic aperture radar (SAR) missions with short repeat times bring the opportunity to get large-scale deformations in near real-time. Since nonstationary deformation is more ...
Los Angeles—Artificial intelligence (AI)-based drug discovery continues to tout accelerated timelines and novel and effective treatments, yet today’s clinical success rates remain at a low 10%. On ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results